Cullinan Therapeutics, Inc. Stock Analysis & AI Score
Cullinan Therapeutics, Inc. (CGEM) has an ST Score of 54.7 (B-), driven by its Forecast (A) and held back by its Growth (C-). Analysts rate it Buy with a $34.75 price target (+125.1% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Cullinan Therapeutics, Inc. (CGEM) has an ST Score of 54.7 (B-), driven by its Forecast (A) and held back by its Growth (C-). Analysts rate it Buy with a $34.75 price target (+125.1% upside).
- Strongest
- ForecastA
- Weakest
- GrowthC-
All factor grades
- ForecastA
- ValuationA-
- Financial StrengthA-
- MomentumB
- SentimentC+
- ProfitabilityC-
- GrowthC-
- Piotroski1/9
Contact
CGEM stock: frequently asked questions
What is CGEM's ST Score?
Cullinan Therapeutics, Inc. (CGEM) has an ST Score of 54.7 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is CGEM a buy, hold, or sell?
Analysts rate CGEM a Buy, with a price target of $34.75 (+125.1% vs the current price). Our ST Score grades it B- (54.7/100). The ST Score is a data-driven signal, not a recommendation.
What are CGEM's factor grades?
Valuation A-, Profitability C-, Financial Strength A-, Momentum B, Growth C-, Forecast A, Sentiment C+.
What is CGEM's valuation grade?
Cullinan Therapeutics, Inc. (CGEM) earns a valuation grade of A-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is CGEM's growth grade?
Cullinan Therapeutics, Inc. (CGEM) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is CGEM's profitability grade?
Cullinan Therapeutics, Inc. (CGEM) earns a profitability grade of C-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is CGEM's financial strength grade?
Cullinan Therapeutics, Inc. (CGEM) earns a financial strength grade of A-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for CGEM?
The average analyst price target for Cullinan Therapeutics, Inc. (CGEM) is $34.75 from 8 analysts, which is +125.1% versus the recent price of $15.44.
What is CGEM's Piotroski score?
Cullinan Therapeutics, Inc. (CGEM) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.